tiprankstipranks
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
PremiumPress ReleasesRevolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
15d ago
Revolution Medicines to Participate in Upcoming Investor Conferences
PremiumPress Releases
Revolution Medicines to Participate in Upcoming Investor Conferences
19d ago
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
PremiumPress Releases
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
26d ago
Revolution Medicines price target raised to $42 from $41 at Wedbush
PremiumThe FlyRevolution Medicines price target raised to $42 from $41 at Wedbush
2M ago
Revolution Medicines sees FY24 GAAP net loss  $480M-$520M
PremiumThe Fly
Revolution Medicines sees FY24 GAAP net loss $480M-$520M
2M ago
Revolution Medicines reports Q4 EPS ($1.14) , consensus (88c)
PremiumThe Fly
Revolution Medicines reports Q4 EPS ($1.14) , consensus (88c)
2M ago
Carnival upgraded, PayPal downgraded: Wall Street’s top analyst calls
PremiumThe FlyCarnival upgraded, PayPal downgraded: Wall Street’s top analyst calls
4M ago
Revolution Medicines upgraded to Buy at BofA ahead of added 2024 data updates
PremiumThe Fly
Revolution Medicines upgraded to Buy at BofA ahead of added 2024 data updates
4M ago
Revolution Medicines upgraded to Buy from Neutral at BofA
PremiumThe Fly
Revolution Medicines upgraded to Buy from Neutral at BofA
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100